Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/424"
Predicate | Value (sorted: none) |
---|---|
rdf:type | |
rdf:type | |
rdfs:label | |
?:Evidence_type | |
?:Evidence_enzyme_system | |
?:Evidence_object_dose | |
?:Evidence_precip_dose | |
?:Evidence_value | |
dc:creator | |
dc:date |
"10/16/2007 11:03:11"
|
?:content |
""When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold. Nefazodone plasma concentrations were unaffected by triazolam. Coadministration of nefazodone potentiated the effects of triazolam on psychomotor performance tests. ""
|
rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ nefazodone_increases_auc_triazolam, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1265 }